Based on the results of pre-clinical and clinical trials conducted by SanBio, Teijin plans to begin clinical trials in Japan.
SanBio developed SB623 by processing bone marrow from donors for introduction into the brains of stroke patients, in order to promote regeneration of damaged central nervous neuronal cells. SB623 has shown remarkable positive results in mammal animals, said the company.
Going forward, Teijin intends to expand its involvement in the regenerative market by developing medicines and treatments that improve the quality of life for people suffering from stroke and related sequelae.